Isabella Palazzolo

Isabella Palazzolo currently serves as the Director at Intellia Therapeutics, Inc. since June 2022, following a role as Associate Director in Regulatory Affairs CMC for Gene Therapy at Biogen from April 2020 to June 2022. Prior to this, Isabella worked at Eli Lilly and Company as a Research Scientist in Global Regulatory Affairs CMC (June 2016 - April 2020), and held multiple positions at Biogen between September 2012 and June 2016, including Manager and Senior Associate II roles in Regulatory Affairs CMC. Earlier research experience includes a Research Fellowship at Massachusetts General Hospital focused on protein clearance mechanisms in Huntington's and Kennedy's Diseases, as well as a Visiting Fellowship at the National Institutes of Health on neurodegeneration, particularly spinal and bulbar muscular atrophy (SBMA). Isabella holds a PhD in Endocrinology and a D.Sc. in Pharmaceutical Biotechnologies from Università degli Studi di Milano. Skills include Microsoft Project, submission planning document preparation, and proficiency with Trackwise and Change Control systems.